Dr. Ranjana Advani

Treatments

• Lymphoma
• Extra Corporeal Shockwave Therapy

Fellowships

• Stanford University School of Medicine,Stanford, Ca, United States   1996

Publications

• Leukemia & lymphomaBevacizumab and cyclosphosphamide, doxorubicin2014
• Jourl of clinical oncologyMature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte2014
• BloodPhase 2 study of VcR-CVAD with maintence rituximab for untreated mantle cell lymphoma2014
• NEW ENGLAND JOURL OF MEDICINETargeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma2013
• JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKTargeted Therapy in Relapsed Classical Hodgkin Lymphoma2013
• BloodPlasma Epstein-Barr virus D predicts outcome in advanced Hodgkin lymphoma2013
• NEW ENGLAND JOURL OF MEDICINEDose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastil B-Cell Lymphoma2013
• ANLS OF ONCOLOGYEfficacy of abbreviated Stanford V chemotherapy2013
• BRITISH JOURL OF HAEMATOLOGYThe efficacy and tolerability of adriamycin, bleomycin2013
• JOURL OF CLINICAL ONCOLOGYRandomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally2013
• JOURL OF CLINICAL ONCOLOGYRisk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma2013
• JOURL OF CLINICAL ONCOLOGYBruton Tyrosine Kise Inhibitor Ibrutinib2013
• JOURL OF CLINICAL ONCOLOGYPhase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin2012
• ONCOLOGISTBrentuximab Vedotin in Transplant-ive Patients with Relapsed or Refractory Hodgkin Lymphoma2012
• JOURL OF CLINICAL ONCOLOGYBrentuximab Vedotin2012
• LEUKEMIA & LYMPHOMACardiac toxicity associated with bevacizumab2012
• INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICSSTAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS2011
• CLINICAL CANCER RESEARCHMicroRs Are Independent Predictors of Outcome in Diffuse Large B2011
• LEUKEMIA & LYMPHOMACurrent concepts and controversies in the magement of early stage Hodgkin lymphoma2011
• Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E.Comparison of conventiol prognostic indices in patients older than 60 years with diffuse large B2010
• EXPERT REVIEW OF ANTICANCER THERAPYRisk stratification in extranodal tural killer/T-cell lymphoma2010
• LANCET ONCOLOGYMagement of T-cell and tural-killer-cell neoplasms in Asia2009
• JOURL OF CLINICAL ONCOLOGYPhase I Study of the Humanized Anti2009
• JOURL OF CLINICAL ONCOLOGYImpact of positive positron emission tomography2007
• JOURL OF CLINICAL ONCOLOGYStage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy2004
• BRITISH JOURL OF HAEMATOLOGYA multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era2014
• LEUKEMIA & LYMPHOMAA multicenter phase II trial to determine the safety2013
• JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines2013
• Jourl of the tiol Comprehensive Cancer NetworkNon-Hodgkin's lymphomas, version 1.2013.2013
• JOURL OF CLINICAL ONCOLOGYGene Expression-Based Model Using Formalin-Fixed Paraffin2013
• Jourl of the tiol Comprehensive Cancer NetworkNon-Hodgkin's Lymphomas, version 3.2012.2012
• JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines2012
• PLOS ONESingle Cell Profiling of Circulating Tumor Cells2012
• JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKHodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines2012
• BLOODIn situ vaccition against mycosis fungoides by intratumoral injection of a TLR92012
• INVESTIGATIOL NEW DRUGSPhase I trial of oblimersen (GesenseA (R)) and gemcitabine in refractory and advanced maligncies2011
• Jourl of the tiol Comprehensive Cancer NetworkHodgkin lymphoma.2011
• JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKNCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma2011
• OBSTETRICS AND GYNECOLOGYLymphoma in Pregncy Initially Diagnosed as Vagil Intraepithelial Neoplasia and Lichen Planus2011
• JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas2011
• JOURL OF THE AMERICAN COLLEGE OF RADIOLOGYACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II2011
• SCIENCE TRANSLATIOL MEDICINECD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma2011
• JOURL OF CLINICAL ONCOLOGYIn Situ Vaccition With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study2010
• JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas2010
• Jourl of the tiol Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.2010
• BRITISH JOURL OF HAEMATOLOGYLymphoma cell VEGFR2 expression detected2010
• CURRENT OPINION IN ONCOLOGYThe emerging role for rituximab in the treatment of nodular lymphocyte predomint Hodgkin lymphoma2009
• ARCHIVES OF DERMATOLOGYPrognostic Factors in Primary Cutaneous Aplastic Large Cell Lymphoma2009
• LEUKEMIA & LYMPHOMAExtranodal tural killer/T-cell lymphoma: current concepts in biology and treatment2009
• ONCOLOGY RESEARCHDymic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr2009
• JOURL OF THE AMERICAN ACADEMY OF DERMATOLOGYIndolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab2008
• Clinical advances in hematology & oncology : H&OEvaluation and magement of angioimmunoblastic T-cell lymphoma2008
• Jourl of the tiol Comprehensive Cancer NetworkHodgkin disease/lymphoma.2008
• Jourl of the tiol Comprehensive Cancer NetworkBeyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.2008
• Jourl of the tiol Comprehensive Cancer NetworkNon-Hodgkin's lymphomas.2008
• Jourl of the tiol Comprehensive Cancer NetworkNon-Hodgkin's lymphoma. Clinical practice guidelines in oncology.2006
• Jourl of the tiol Comprehensive Cancer NetworkHodgkin disease/lymphoma. Clinical practice guidelines in oncology.2006
• Jourl of the tiol Comprehensive Cancer NetworkMagement of advanced stage Hodgkin lymphoma.2006
• ANLS OF ONCOLOGYA phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)2005
• INVESTIGATIOL NEW DRUGSA phase I trial of aprinocarsen (ISIS 3521/LY900003)2005
• Investigatiol New Drugs,A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003)2005
• JOURL OF CLINICAL ONCOLOGYMitoxantrone, etoposide2004
• CLINICAL CANCER RESEARCHPhase I and pharmacokinetic study of BMS-188797, a new taxane alog2003
• BloodTreatment of refractory1999
• Leukemia & lymphomaBevacizumab and cyclosphosphamide, doxorubicin2014
• Journal of clinical oncologyMature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte2014
• BloodPhase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma2014
• BloodImprovements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades2013
• NEW ENGLAND JOURNAL OF MEDICINETargeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma2013
• JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKTargeted Therapy in Relapsed Classical Hodgkin Lymphoma2013
• BloodPlasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma2013
• NEW ENGLAND JOURNAL OF MEDICINEDose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma2013
• ANNALS OF ONCOLOGYEfficacy of abbreviated Stanford V chemotherapy2013
• BRITISH JOURNAL OF HAEMATOLOGYThe efficacy and tolerability of adriamycin, bleomycin2013
• JOURNAL OF CLINICAL ONCOLOGYRandomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally2013
• JOURNAL OF CLINICAL ONCOLOGYRisk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma2013
• BLOODMulticenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma2013
• JOURNAL OF CLINICAL ONCOLOGYBruton Tyrosine Kinase Inhibitor Ibrutinib2013
• BLOODTumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma2012
• JOURNAL OF CLINICAL ONCOLOGYPhase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin2012
• ONCOLOGISTBrentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma2012
• JOURNAL OF CLINICAL ONCOLOGYBrentuximab Vedotin2012
• LEUKEMIA & LYMPHOMACardiac toxicity associated with bevacizumab2012
• INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSSTAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS2011
• CLINICAL CANCER RESEARCHMicroRNAs Are Independent Predictors of Outcome in Diffuse Large B2011
• LEUKEMIA & LYMPHOMACurrent concepts and controversies in the management of early stage Hodgkin lymphoma2011
• Hematology / the Education Program of the American Society of HematoloOptimal therapy of advanced Hodgkin lymphoma.2011
• Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E.Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B2010
• EXPERT REVIEW OF ANTICANCER THERAPYRisk stratification in extranodal natural killer/T-cell lymphoma2010
• Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes2009
• LANCET ONCOLOGYManagement of T-cell and natural-killer-cell neoplasms in Asia2009
• JOURNAL OF CLINICAL ONCOLOGYPhase I Study of the Humanized Anti2009
• JOURNAL OF CLINICAL ONCOLOGYImpact of positive positron emission tomography on prediction of freedom from progression after2007
• LEUKEMIA & LYMPHOMAAngioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine2007
• JOURNAL OF CLINICAL ONCOLOGYStage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy2004
• Pediatric blood & cancerACR appropriateness Criteria® pediatric Hodgkin lymphoma.2014
• BRITISH JOURNAL OF HAEMATOLOGYA multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era2014
• ONCOLOGY-NEW YORKACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma2013
• LEUKEMIA & LYMPHOMAA multicenter phase II trial to determine the safety2013
• JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines2013
• Journal of the National Comprehensive Cancer NetworkNon-Hodgkin's lymphomas, version 1.2013.2013
• JOURNAL OF CLINICAL ONCOLOGYGene Expression-Based Model Using Formalin2013
• Journal of the National Comprehensive Cancer NetworkNon-Hodgkin's Lymphomas, version 3.2012.2012
• JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines2012
• PLOS ONESingle Cell Profiling of Circulating Tumor Cells2012
• JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKHodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines2012
• RADIATION ONCOLOGYInterim-treatment quantitative PET parameters predict progression2012
• BLOODIn situ vaccination against mycosis fungoides by intratumoral injection of a TLR92012
• CLINICAL CANCER RESEARCHA Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed2012
• INVESTIGATIONAL NEW DRUGSPhase I trial of oblimersen (GenasenseA (R)) and gemcitabine2011
• Journal of the National Comprehensive Cancer NetworkHodgkin lymphoma.2011
• JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKNCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma2011
• BLOODPrediction of survival in diffuse large B2011
• OBSTETRICS AND GYNECOLOGYLymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus2011
• JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas2011
• JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGYACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II2011
• SCIENCE TRANSLATIONAL MEDICINECD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma2011
• Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, Prediction of Survival In Diffuse Large B2010
• JOURNAL OF CLINICAL ONCOLOGYIn Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study2010
• CURRENT PROBLEMS IN CANCERACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma2010
• CLINICAL CANCER RESEARCHVoreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed2010
• JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKNon-Hodgkin's Lymphomas2010
• Journal of the National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.2010
• BLOODInterim positron emission tomography scans in diffuse large B-cell lymphoma2010
• BRITISH JOURNAL OF HAEMATOLOGYLymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival2010
• CURRENT OPINION IN ONCOLOGYThe emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma2009
• ARCHIVES OF DERMATOLOGYPrognostic Factors in Primary Cutaneous Anapl2009
• Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR)0
• CLINICAL LYMPHOMA & MYELOMATargeting CD40 in Waldenstrom's Macroglobulinemia2009
• LEUKEMIA & LYMPHOMAExtranodal natural killer/T-cell lymphoma: current concepts in biology and treatment2009
• ONCOLOGY RESEARCHDynamic CD8 T-Cell Responses to Tumor2009
• JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGYIndolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab2008
• Clinical advances in hematology & oncology : H&OEvaluation and management of angioimmunoblastic T-cell lymphoma2008
• Journal of the National Comprehensive Cancer NetworkHodgkin disease/lymphoma.2008
• BLOODParaffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with2008
• Journal of the National Comprehensive Cancer NetworkBeyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.2008
• Journal of the National Comprehensive Cancer NetworkNon-Hodgkin's lymphomas.2008
• CANCERNon-Hodgkin lymphoma of the breast2007
• CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGYTreatment of mantle cell lymphoma: Current approach and future directions2006
• ARCHIVES OF DERMATOLOGYStaging accuracy in mycosis fungoides2006
• Journal of the National Comprehensive Cancer NetworkNon-Hodgkin's lymphoma. Clinical practice guidelines in oncology.2006
• Journal of the National Comprehensive Cancer NetworkHodgkin disease/lymphoma. Clinical practice guidelines in oncology.2006
• Journal of the National Comprehensive Cancer NetworkManagement of advanced stage Hodgkin lymphoma.2006
• ANNALS OF ONCOLOGYA phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)2005
• INVESTIGATIONAL NEW DRUGSA phase I trial of aprinocarsen (ISIS 3521/LY900003)2005
• Investigational New Drugs,A phase I trial of aprinocarsen (ISIS 3521/LY900003)2005
• JOURNAL OF CLINICAL ONCOLOGYMitoxantrone, etoposide2004
• CLINICAL CANCER RESEARCHPhase I and pharmacokinetic study of BMS-188797, a new taxane analog2003
• Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., LitcA phase I trial of doxorubicin, paclitaxel2001
• BloodTreatment of refractory1999

Dr. Ranjana Advani's Practice location